Literature DB >> 25862846

Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action.

Byron Baron1, Yufeng Wang2, Shin-Ichiro Maehara3, Yoshihiko Maehara3, Yasuhiro Kuramitsu2, Kazuyuki Nakamura4.   

Abstract

BACKGROUND/AIM: The pancreatic cancer cell line KLM1 can gain chemoresistance following gemcitabine (GEM) treatment. Metformin was found to be a useful sensitising agent towards GEM treatment following gain of chemoresistance.
MATERIALS AND METHODS: The proliferation of GEM-sensitive and -resistant cells was investigated over a range of metformin concentrations from 0.005 to 5 mM. The intra- and extra-cellular energetic profiles of these two cell types under metformin exposure were investigated through adenosine triphosphate (ATP) and L-lactate assays.
RESULTS: There was an unexpected decrease in intracellular L-lactate following gain of chemoresistance, despite observable medium acidification. At the biochemical level, a marked effect on phosphorylated proteins upstream of Akt, along the mTOR pathway, was observed at 6 h. These changes followed a time-dependent pattern linked closely to the changes in the energetic profile.
CONCLUSION: Together, these results indicate that metformin indirectly blocks protein phosphorylation, including that of heat shock protein 27 (HSP27). Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  HSP27; metformin; pancreatic cancer

Mesh:

Substances:

Year:  2015        PMID: 25862846

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism.

Authors:  Yong Liu; Chunxi He; Xianping Huang
Journal:  Oncotarget       Date:  2017-09-06

2.  Metformin Inhibits Gemcitabine Induced Apoptosis in Pancreatic Cancer Cell Lines.

Authors:  Dietmar Zechner; Ann-Christin Albert; Florian Bürtin; Brigitte Vollmar
Journal:  J Cancer       Date:  2017-07-01       Impact factor: 4.207

3.  Cohort Study of Antihyperglycemic Medication and Pancreatic Cancer Patients Survival.

Authors:  Audrius Dulskas; Ausvydas Patasius; Donata Linkeviciute-Ulinskiene; Lina Zabuliene; Giedre Smailyte
Journal:  Int J Environ Res Public Health       Date:  2020-08-19       Impact factor: 3.390

4.  Modified Gold Nanoparticles to Overcome the Chemoresistance to Gemcitabine in Mutant p53 Cancer Cells.

Authors:  Eduardo García-Garrido; Marco Cordani; Álvaro Somoza
Journal:  Pharmaceutics       Date:  2021-12-03       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.